These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 17053349

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients.
    Keh CE, Shen JM, Hahn B, Hallahan CW, Rehm CA, Thaker V, Wynne SM, Davey RT, Lane HC, Sereti I.
    AIDS; 2006 Feb 14; 20(3):361-9. PubMed ID: 16439869
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy.
    Orsilles MA, Pieri E, Cooke P, Caula C.
    APMIS; 2006 Jan 14; 114(1):55-60. PubMed ID: 16499662
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.
    Antivir Ther; 2007 Jan 14; 12(6):971-5. PubMed ID: 17926652
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Apoptosis of naive CD4+ T-cells from HIV-infected patients with poor immune response to HAART is enhanced in vitro by steroid.
    Roger PM, Perbost I, Ticchioni M, Fuzibet JG, Breittmayer JP, Durant J, Pesce A, Bernard A, Dellamonica P, Groupe d'Etudes Niçois Polyvalent en Infectiologie.
    J Infect; 2004 Oct 14; 49(3):216-21. PubMed ID: 15337338
    [Abstract] [Full Text] [Related]

  • 31. Changes in T-cell subpopulations during four years of suppression of HIV-1 replication in patients with advanced disease.
    Lepej SZ, Begovac J, Vince A.
    FEMS Immunol Med Microbiol; 2006 Apr 14; 46(3):351-9. PubMed ID: 16553807
    [Abstract] [Full Text] [Related]

  • 32. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients.
    Almeida M, Cordero M, Almeida J, Orfao A.
    Cytometry B Clin Cytom; 2007 Jan 15; 72(1):22-33. PubMed ID: 17051525
    [Abstract] [Full Text] [Related]

  • 33. Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential.
    Beq S, Delfraissy JF, Theze J.
    Eur Cytokine Netw; 2004 Jan 15; 15(4):279-89. PubMed ID: 15627636
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R.
    J Infect Dis; 2006 Jul 01; 194(1):29-37. PubMed ID: 16741879
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load.
    Arnó A, Ruiz L, Juan M, Jou A, Balagué M, Zayat MK, Marfil S, Martínez-Picado J, Martínez MA, Romeu J, Pujol-Borrell R, Lane C, Clotet B.
    J Infect Dis; 1999 Jul 01; 180(1):56-60. PubMed ID: 10353861
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
    Akerele T, Galatowicz G, Bunce C, Calder V, Lynn WA, Lightman S.
    Clin Immunol; 2006 Nov 01; 121(2):191-7. PubMed ID: 16987710
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.